Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement expands an existing customer relationship and includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms.
The engagement covers development and clinical manufacturing services for an investigational oncology product. Revenue is expected during 2026 and 2027, with stability services extending beyond 2027. This timeline suggests a multi-year revenue stream that could provide Scinai with predictable cash flow as it continues to advance its own immunology pipeline.
Following the agreement, Scinai’s committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million. That figure represents a 300% increase from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. Such growth underscores the company’s expanding role as a CDMO and signals rising demand for its manufacturing expertise.
The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones. If realized, these opportunities could push total committed and potential revenue well above $13 million, further strengthening Scinai’s financial position.
For investors, the deal matters because it demonstrates Scinai’s ability to convert its CDMO capabilities into significant, recurring revenue. The 300% jump in committed orders highlights operational execution and could improve the company’s valuation as it scales. Moreover, the agreement with a Nasdaq-listed biopharmaceutical company lends external validation to Scinai’s manufacturing quality and reliability.
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is focused on developing innovative immunology therapies and is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., which provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For more information, please visit MissionIR.
